Gilead to initiate two Phase 3 studies for coronav
Post# of 148184
(Total Views: 371)
Posted On: 02/26/2020 5:22:00 PM
Gilead to initiate two Phase 3 studies for coronavirus
Gilead Sciences (NASDAQ:GILD) +2.5% is starting the studies for the safety and efficacy of remdesivir in adults with Covid-19, or novel coronavirus.
Starting in March, the studies will enroll about 1,000 patients in medical centers primarily located in Asia and other countries with a high number of diagnosed coronavirus cases.
One study will randomize 400 patients with severe Covid-19 to receive either five or 10 days of remdesivir. The other study includes 600 moderate patients receiving the same dosage or standard of care alone
Gilead Sciences (NASDAQ:GILD) +2.5% is starting the studies for the safety and efficacy of remdesivir in adults with Covid-19, or novel coronavirus.
Starting in March, the studies will enroll about 1,000 patients in medical centers primarily located in Asia and other countries with a high number of diagnosed coronavirus cases.
One study will randomize 400 patients with severe Covid-19 to receive either five or 10 days of remdesivir. The other study includes 600 moderate patients receiving the same dosage or standard of care alone
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼